<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:department>Clinical Sciences</gtr:department><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/02405512-3310-4E12-AF21-E7777A3BEA1B"><gtr:id>02405512-3310-4E12-AF21-E7777A3BEA1B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Gordon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FC81D929-4106-404F-8E94-4B66DD7F4224"><gtr:id>FC81D929-4106-404F-8E94-4B66DD7F4224</gtr:id><gtr:firstName>Daniela</gtr:firstName><gtr:otherNames>M.</gtr:otherNames><gtr:surname>Ferreira</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FM011569%2F1"><gtr:id>261FE158-24AD-421F-93EF-60E6A709B096</gtr:id><gtr:title>Experimental Human Pneumococcal Carriage to determine optimal protection from carriage and mechanisms of mucosal immunisation against disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M011569/1</gtr:grantReference><gtr:abstractText>Streptococcus pneumoniae is the most common bacterial cause of pneumonia, meningitis and otitis media in children world-wide. In adults, pneumococcal pneumonia is a common and increasing cause of hospital admission with substantial mortality in the elderly. In addition, pneumococcal infections cause exacerbations of chronic lung disease, particularly COPD and asthma. An important paradox in pneumococcal infection, however, is that in the vast majority of people these bacteria are occasionally found harmlessly inhabiting the naso-pharynx. This harmless state, termed pneumococcal carriage, boosts immunity to pneumococcal disease and is therefore of some benefit but can also be the means by which infection is transmitted. Pneumococcal carriage is considered to be the key to controlling disease as it is the means of transmission and the prerequisite of disease.

Vaccination is the most important and effective intervention in the prevention of pneumococcal disease but the weapons in this armoury are still far from optimal in terms of expense and coverage of pneumococcal types. Current vaccines have, however, demonstrated that effective prevention of both pneumococcal carriage and disease is possible in young children, with indirect benefit to unvaccinated adults resulting from reduction of circulating pneumococcal carriage. It is less clear how current vaccines should be used directly in adults, or those with chronic disease. It is also unclear by what mechanism vaccines alter carriage and which vaccines are most effective in this regard. There are many new vaccines at early stages of development and studies of how they influence carriage could be important in choosing between possible alternatives.

This Experimental Human Pneumococcal Carriage (EHPC) Programme Grant will make use of studies in healthy volunteers and patients with increased risk of pneumococcal disease to determine the immune responses in health that are protective against pneumococcal carriage. We have developed a method, unique in the world, for inoculating humans safely in order to establish carriage experimentally and have now tested it in over 300 subjects without adverse effects. This model of natural carriage can be used to (a) discover how healthy subjects make immune responses to carriage, (b) discover how subjects with risk factors (age, chronic lung disease) make responses to carriage and how this is different from healthy people, (c) test new vaccines for their effect in experimental carriage and (d) discover how the host alters the biology of the bacteria while it is being carried. Testing new vaccines using EHPC can be done more quickly and at a fraction of the cost of clinical studies (100 subjects rather than many thousands) and so several vaccines can be tested during this Programme, in parallel with the discovery science. This Programme also offers an opportunity for partnership with commercial entities or charities sponsoring particular new vaccines and these funding options will be explored with MRC.

In summary, This EHPC Programme will run and coordinate the maximum use of a unique human pneumococcal challenge model to study host/pathogen interactions critical to the prevention of pneumococcal disease by vaccination. We will use a variety of pneumococcal strains to challenge human volunteers, both healthy and with risk factors for pneumococcal disease, in order to determine factors underlying susceptibility and protection from disease. We will manage a portfolio of commercial vaccine development studies using the human challenge model in parallel with the science discovery programme.</gtr:abstractText><gtr:technicalSummary>Pneumococcal disease remains a research priority world-wide with high mortality from meningitis, pneumonia and sepsis and high morbidity and expense from otitis media. Conjugate vaccination programmes have shown that both carriage and disease can be prevented leading to substantial direct and additional very large herd benefits by reduction of carriage. There could be important additional gain, however, from bringing protein vaccines to licensure in order to gain from wide strain coverage, reduced production expense and potential combination with conjugates.

This Experimental Human Pneumococcal Carriage (EHPC) Programme will coordinate maximum use of a human pneumococcal challenge model to study host/pathogen interactions critical to the prevention of pneumococcal carriage and disease by vaccination. We will use a variety of pneumococcal strains to experimentally challenge human volunteers with bacteria. We will recruit both healthy subjects and those with risk factors for pneumococcal disease in order to determine both pathogen and host factors that determine susceptibility and correlates of protection. We will manage a portfolio of commercial vaccine development studies using the human challenge model in parallel with the science discovery programme.

The EHPC platform itself requires a complex, expensive integrated team including clinical, microbiological and immunological teams. In order to fully exploit the scientific potential of the platform, we have established collaborations with 20 other laboratories, predominantly in the UK. Our collaborators bring outstanding international expertise, a shared vision of global vaccination against pneumococcal disease and the offer of practical help in accessing the necessary additional resources to apply cutting-edge technology to the samples this model will generate.</gtr:technicalSummary><gtr:potentialImpactText>This Programme is about vaccine development. The Programme will impact scientists, commercial partners and the public across the translational spectrum and will eventually benefit the most vulnerable populations that suffer with the high burden of pneumococcal disease.

1) Impact on scientists
See section above.

2) Impact on commercial sector 
There is a logistic roadblock to novel vaccine testing as discussed in the Case for Support. This programme will make early clinical testing of novel vaccines a reasonable prospect and so alter the risk-benefit balance for companies considering novel vaccine programmes. Commercial partners will be able to investigate whether their vaccine candidates can protect against carriage in a phase 1-2 trial involving a relative small number of subjects. The information on increased susceptibility of the elderly and asthmatics to pneumococcal diseases will also be very relevant for the development of novel vaccines that will benefit these groups.

3) Impact on susceptible populations and vulnerable minorities
The development of a novel and more effective pneumococcal vaccine will benefit susceptible populations. The most susceptible groups of adults, particularly the elderly and patients with asthma and COPD will benefit from a more direct vaccine discovery approach. The global burden of pneumococcal disease and carriage is highest in vulnerable least-economically-developed-countries (LEDC) due to malnutrition, HIV burden and co-infections. This Programme does not directly address these populations but progress in vaccine discovery will alter the prospects for countries currently lacking a pneumococcal vaccine strategy.

3) Impact on vaccine policy
There is current controversy regarding the efficacy of current polysaccharide-based vaccines, particularly in adults. Preferred vaccines would prevent transmission by blocking carriage; some of the data required in these decisions could be obtained by focused studies using EHPC to determine the prevention of carriage by new vaccines. 

4) Impact on general public
Public involvement. Our public engagement programme will disseminate knowledge on pneumonia and benefits of vaccination during news releases from our group, school talks, and social media (twitter and facebook). LSTM have a strong past record of successful public engagement and are committed to improving the public understanding of science. We will encourage our collaborators on this programme grant to take part in our public engagement activities.
 
5) Impact on all staff and students
Students: Samples and data generated during this programme grant will enable several PhD projects to be developed both at the Respiratory Infection group at LSTM and in our collaborators laboratories. 
Staff: The parallel commercial Work Package in the Programme will allow staff ordinarily in an academic environment to learn more of the regulatory and other challenges that form part of bringing a new vaccine to licensure. This Programme will also give the opportunity for short-term internship and exchange visits between collaborators laboratories and the Respiratory Infection group at LSTM.</gtr:potentialImpactText><gtr:fund><gtr:end>2020-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2295295</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Controlled Human Infection Models Consortium - Gates Foundation</gtr:description><gtr:id>49D435FC-5792-45EB-B324-296CA3BEE605</gtr:id><gtr:impact>CHIM are currently available for a range of enteric, respiratory, and vector-borne diseases, and have played a key role in the development of some of the vaccines we use today. The wider use of CHIM could further accelerate development of candidate vaccines, in part by the early elimination of some candidate vaccines while advancing others to field efficacy trials. CHIM studies are also an important source of information about immune responses to infection and vaccination.</gtr:impact><gtr:partnerContribution>D Ferreira was invited to be a member of the BMGF CHIM Scientific Leadership group. The panel discussed how this consortium could facilitate CHIM research by sharing information, SOPs, protocol and agents for infection.</gtr:partnerContribution><gtr:piContribution>n/a</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University of Tokyo - EHPC collaboration meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FEDFBE63-AEA9-4284-A2B9-2DF08BE29D84</gtr:id><gtr:impact>A meeting between LSTM and Tokyo university to discuss the a joint grant application to the MRC DPFS as part of a new collaboration to develop mucosal vaccines based on PspA antigen. This collaboration resulted from the visit of Dr Ferreira to Butantan Institute (Sao Paulo) as part of the MRC/FAPESP award.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Twitter Feed (@Liv_RRN)</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>43B89F5B-1DE3-4783-BF06-15EA6DDAA7CB</gtr:id><gtr:impact>Twitter feed used to encourage study participation and inform donors and collaborators of current policy</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Facebook page</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E10FA2F9-DD63-4260-A833-0AD667695587</gtr:id><gtr:impact>Facebook page advertises studies and informs on latest study developments, currently over 60 members and a footprint of over 1000 people</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/LivRRC/?ref=aymt_homepage_panel</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Symposium on Pneumococci and Pneumococcal Diseases -  Conference Glasgow</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>553DAC47-1F67-4F53-A709-B76BAD336875</gtr:id><gtr:impact>Collaboration between Rick Malley, Daniela Ferreira and Eliane Miyagi to screen a library of &amp;gt;60 pneumococcal proteins for correlates or protection against carriage acquisition.

Discussions between Immbio and Daniela Ferreira led to an agreement to analyze IL-17 responses to PnuBioVax from a phase I clinical trial.

Initial contacts between Tim Mitchell and Daniela Ferreira groups to collaborate on neutrophil function in elderly individuals and experimental carriage.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic visit and Talk at Butantan Institute and University of Sao Paulo.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>518CC53A-8134-4D64-9F3C-D39A03BDCC95</gtr:id><gtr:impact>Postgraduate, undergraduate students and principal investigators attended these two seminars which sparked questions and discussion afterwards. This visit initiated the visit of two academics from Brazil to the LSTM in 2017 (Helder Nakaya and Alessandra Schanoski).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Liverpool Freshers Fair</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DA40D0B-CC28-4233-B159-AD5E67B13294</gtr:id><gtr:impact>University freshers fair. A stand was hired to allow nurses and clinical staff to engage with students and encourage enrollment on clinical studies for LAIV and EHPC</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XII European Meeting on the Molecular Biology of the Pneumococcus, Europneumo, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C4E777CD-8365-4F0C-B0F0-CF348DCF42F8</gtr:id><gtr:impact>Talk to disseminate research findings during this conference. Breakfast meeting with approximately 20 EHPC collaborators to discuss the EHPC Programme planned activities.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th International Symposium on Pneumococci and Pneumococcal Diseases, ISPPD-9, India</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>57CCEC5F-A4F4-4145-9727-75AC68EB0988</gtr:id><gtr:impact>Talk to disseminate research findings and discussion of future collaborative activities

tbc</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Liverpool School of Tropical Medicine - Open day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8B28260C-C4CE-4C72-868D-6B7EB567268D</gtr:id><gtr:impact>Visitors were given the opportunity to talk to researchers and educators as well as current and previous students about their experiences of studying at LSTM. There were a number of demonstrations from research staff highlighting the work carried out in the laboratories on site and in numerous countries overseas. 

The afternoon was a great success, providing an opportunity for prospective students to discover more about our courses and research options and, most importantly, giving them the chance to talk to teaching staff and current students and alumni about their experiences of studying here.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.lstmed.ac.uk/news-events/news/lstm-postgraduate-open-day</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Advertisements for healthy trial volunteers to take part in EHPC studies</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2C7709D0-2F31-4B33-B3F9-F39C3B5C2AFB</gtr:id><gtr:impact>This activity resulted in enquiries from the general public about how they can get involved in clinicial trials associated with EHPC

We were able to recruit several volunteers to our studies</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LAIV Recruitment Events / Activities targeted: - University Library; University of Liverpool Freshers Fairs; Liverpool John Moores Freshers Fair; Liverpool Hope University Freshers Fairs; University of Liverpool Sports Fair; Crown Place and Greenbank Halls of Residence; Vine Court Halls of Residence.</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>696B46C1-8E37-49E8-81D4-A3F6BE4EBCB3</gtr:id><gtr:impact>From these engagement activities we gained 1700 contacts for further discussions, leading to potential entry into our studies.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>John Moores University Re-Freshers Fair</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4278582B-90F5-4CD7-8326-49EDA62207B0</gtr:id><gtr:impact>Re-Freshers fair for university students - 2000 footfall with 80+ requests for further information on enrolling onto clinical studies</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Bill and Melinda Gates Foundation - Supplement Grant</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1117728</gtr:fundingRef><gtr:id>29B87316-EF8A-4E09-9B8F-E3161367C50C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Unilever Research and Development</gtr:department><gtr:description>Hand to nose transmission of streptococcus pneumoniae in healthy participants - pilot study</gtr:description><gtr:fundingOrg>Unilever</gtr:fundingOrg><gtr:id>E079D661-9D36-4694-B419-1723EA6AC181</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2518294</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Effect of Live Attenuated and Inactivated Influenza vaccines on Experimental Human Pneumococcal Carriage</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1117728</gtr:fundingRef><gtr:id>A149AE19-8457-4017-A14B-2A5BF446F7F5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>523377</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enhancing mucosal immunity to Streptococcus pneumoniae by nasal administration of live strains attenuated in virulence</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/N02687X/1</gtr:fundingRef><gtr:id>BF776D7D-DCA1-45A5-B1C0-C9489C14CCC9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13515</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Clinical Research Network North West Coast</gtr:department><gtr:description>Additional Funding allocations for NHS Service Support</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>C7B77BBB-F5A2-4684-ADD2-AA1F7688CD48</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>456762</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Vaccine Fapesp MICA : Pulmonary Delivery of a Targeted Mucosal Nanocarrier Vaccine for Pneumonia</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CC324730-FA1C-47CB-A6A1-CA9C0D02B59A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B025C122-2CF7-4052-8853-1440EA9BC348"><gtr:id>B025C122-2CF7-4052-8853-1440EA9BC348</gtr:id><gtr:title>First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/781ae3f1038e660ba69f20caf2de236e"><gtr:id>781ae3f1038e660ba69f20caf2de236e</gtr:id><gtr:otherNames>Collins AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D085EE49-121F-4A38-8C75-F55FCB65D247"><gtr:id>D085EE49-121F-4A38-8C75-F55FCB65D247</gtr:id><gtr:title>Pneumococcal Colonization Rates in Patients Admitted to a United Kingdom Hospital with Lower Respiratory Tract Infection: a Prospective Case-Control Study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/781ae3f1038e660ba69f20caf2de236e"><gtr:id>781ae3f1038e660ba69f20caf2de236e</gtr:id><gtr:otherNames>Collins AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB50CE1A-7F51-401B-ADD4-35C96B010576"><gtr:id>BB50CE1A-7F51-401B-ADD4-35C96B010576</gtr:id><gtr:title>Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/acfb1674ee4f50814fc8a7e1a1e67b6f"><gtr:id>acfb1674ee4f50814fc8a7e1a1e67b6f</gtr:id><gtr:otherNames>Pennington SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/693F10F9-FED0-4ADE-A640-747092E90845"><gtr:id>693F10F9-FED0-4ADE-A640-747092E90845</gtr:id><gtr:title>Oral Typhoid Vaccination With Live-Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a-Responsive and Heterologous Influenza Virus-Responsive CD4+ and CD8+ T Cells at the Human Intestinal Mucosa.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/acfb1674ee4f50814fc8a7e1a1e67b6f"><gtr:id>acfb1674ee4f50814fc8a7e1a1e67b6f</gtr:id><gtr:otherNames>Pennington SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DC68745-BA98-40C5-8E26-E4A17B9D514E"><gtr:id>3DC68745-BA98-40C5-8E26-E4A17B9D514E</gtr:id><gtr:title>Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/590d2b60f78fe38941c9b97776e07bba"><gtr:id>590d2b60f78fe38941c9b97776e07bba</gtr:id><gtr:otherNames>Mitsi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBDE11DC-53CC-41B4-AFF3-0CDD3A9040ED"><gtr:id>DBDE11DC-53CC-41B4-AFF3-0CDD3A9040ED</gtr:id><gtr:title>Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51a033d0f811e26555cef3a06f25b55a"><gtr:id>51a033d0f811e26555cef3a06f25b55a</gtr:id><gtr:otherNames>Glennie S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F84E176-3C1A-4063-9175-226189D0E4B8"><gtr:id>8F84E176-3C1A-4063-9175-226189D0E4B8</gtr:id><gtr:title>Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a5a993ebe72eb5c4f407a0399ee2dda"><gtr:id>8a5a993ebe72eb5c4f407a0399ee2dda</gtr:id><gtr:otherNames>Jochems SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4A3CD0C-991F-45C5-BF3D-655C66B101B2"><gtr:id>D4A3CD0C-991F-45C5-BF3D-655C66B101B2</gtr:id><gtr:title>Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51a033d0f811e26555cef3a06f25b55a"><gtr:id>51a033d0f811e26555cef3a06f25b55a</gtr:id><gtr:otherNames>Glennie S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB96A70B-B126-49C0-9171-68186C434AE5"><gtr:id>AB96A70B-B126-49C0-9171-68186C434AE5</gtr:id><gtr:title>Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8821414bf5a4872f0a5d9944b6b932e9"><gtr:id>8821414bf5a4872f0a5d9944b6b932e9</gtr:id><gtr:otherNames>Kunda NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1CD13BE-51CA-45AA-877D-7C3D5EE894D5"><gtr:id>E1CD13BE-51CA-45AA-877D-7C3D5EE894D5</gtr:id><gtr:title>Genetic stability of pneumococcal isolates during 35 days of human experimental carriage.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aedd029c42eb54bb9f75a7c9b994dbd6"><gtr:id>aedd029c42eb54bb9f75a7c9b994dbd6</gtr:id><gtr:otherNames>Gladstone RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03B22F7C-3889-42F9-91C7-88051934D1C8"><gtr:id>03B22F7C-3889-42F9-91C7-88051934D1C8</gtr:id><gtr:title>Neuraminidase A-Exposed Galactose Promotes Streptococcus pneumoniae Biofilm Formation during Colonization.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ecc77b128ab4ce0e262fb012cf61fc2"><gtr:id>9ecc77b128ab4ce0e262fb012cf61fc2</gtr:id><gtr:otherNames>Blanchette KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7316162-ED40-4702-9C35-B0BB408E7B32"><gtr:id>B7316162-ED40-4702-9C35-B0BB408E7B32</gtr:id><gtr:title>Pneumococcal Colonization Rates in Patients Admitted to a United Kingdom Hospital with Lower Respiratory Tract Infection: a Prospective Case-Control Study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/781ae3f1038e660ba69f20caf2de236e"><gtr:id>781ae3f1038e660ba69f20caf2de236e</gtr:id><gtr:otherNames>Collins AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M011569/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>